Clinical Trials Logo
  1. Home
  2. Lung Cancer, Small Cell
  3. NCT00997061

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome — SCOT  

Lung Cancer, Small Cell Clinical Trial

Official title:
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

Clinical Trial Summary

The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.

Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.

Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.

Clinical Trial Description

n/a

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00997061
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date November 2009
Completion date February 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT00046111 - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT06293833 - Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan N/A
Completed NCT00259935 - A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors Phase 1
Completed NCT01037023 - Regulatory Hycamtin(Oral) PMS N/A
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT00276276 - Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Phase 3
Not yet recruiting NCT05320458 - Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer N/A
Active, not recruiting NCT05228496 - A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC Phase 2
Completed NCT00316186 - First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin Phase 2
Not yet recruiting NCT04440800 - Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Completed NCT00698516 - Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer Phase 2
Terminated NCT03499678 - Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
Terminated NCT01313663 - A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Completed NCT00320359 - Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Phase 3
Completed NCT00043862 - The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Phase 2
Recruiting NCT06228326 - A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Phase 1
Completed NCT04314895 - Trial of NanoPac Intratumoral Injection in Lung Cancer Phase 2